Harvest Fund Management Co. Ltd bought a new stake in Insulet Co. (NASDAQ:PODD - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 2,311 shares of the medical instruments supplier's stock, valued at approximately $603,000.
Several other hedge funds have also recently added to or reduced their stakes in the business. SBI Securities Co. Ltd. acquired a new position in shares of Insulet during the fourth quarter valued at $36,000. SRS Capital Advisors Inc. grew its position in Insulet by 43.1% in the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock valued at $49,000 after buying an additional 56 shares in the last quarter. TD Private Client Wealth LLC grew its position in Insulet by 32.6% in the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier's stock valued at $53,000 after buying an additional 56 shares in the last quarter. Friedenthal Financial acquired a new position in Insulet during the 4th quarter valued at about $57,000. Finally, Assetmark Inc. lifted its stake in shares of Insulet by 1,447.1% in the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock worth $69,000 after acquiring an additional 246 shares during the period.
Insulet Stock Down 0.5 %
Shares of PODD traded down $1.33 during mid-day trading on Tuesday, reaching $272.71. The company's stock had a trading volume of 958,553 shares, compared to its average volume of 690,203. The business has a fifty day moving average of $272.16 and a 200 day moving average of $257.78. The company has a market cap of $19.15 billion, a price-to-earnings ratio of 47.10, a price-to-earnings-growth ratio of 3.62 and a beta of 1.29. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $289.46.
Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, beating analysts' consensus estimates of $1.00 by $0.15. The firm had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. As a group, analysts forecast that Insulet Co. will post 3.92 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of research analysts recently commented on PODD shares. Canaccord Genuity Group raised their price objective on shares of Insulet from $304.00 to $324.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Citigroup lifted their price target on Insulet from $310.00 to $355.00 and gave the company a "buy" rating in a research report on Friday, February 21st. Raymond James restated an "outperform" rating and issued a $328.00 price objective (up previously from $294.00) on shares of Insulet in a report on Friday, February 21st. TD Cowen raised their target price on Insulet from $264.00 to $324.00 and gave the company a "buy" rating in a research note on Friday, January 3rd. Finally, Piper Sandler boosted their price target on shares of Insulet from $285.00 to $310.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Insulet presently has an average rating of "Moderate Buy" and a consensus price target of $292.06.
Read Our Latest Analysis on Insulet
Insider Transactions at Insulet
In other Insulet news, EVP Eric Benjamin sold 12,394 shares of the business's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the transaction, the executive vice president now owns 11,383 shares in the company, valued at $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.47% of the stock is currently owned by company insiders.
About Insulet
(
Free Report)
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.
Recommended Stories
Before you consider Insulet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.
While Insulet currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
